Inflammation the Kingpin of Chronic Diseases Naturopathy as an alternative source of treatment: An updated overview
Inflammation involves a sequence of events which can be categorized under three phases viz. acute transient phase, delayed sub-acute phase and chronic proliferate phase. Inflammatory mediators develop due to enhanced vascular permeability and leads to local edema. It is followed by the migration of leukocytes and phagocytes from blood to vascular tissues which is the second phase, in the third phase, tissue degradation is followed by fibrosis. There is a powerful link between chronic diseases and chronic inflammatory disorders. Chronic low-level inflammation contributes to the pathogenesis of these several diseases like Heart disease, Cancer, Chronic lower respiratory disease, Stroke, Alzheimer’s, Diabetes, and Nephritis. The harmful side effects of synthetic drugs are numerous and there stands up the need of herbal drugs which are cost effective and free from side-effects. Several traditional ayurvedic phytomedicines have been used in the treatment of inflammatory disorders like Ocimum sanctum, Hypericum peroratum, Boswellic serrata, Ficus racemosa etc. which act as natural anti-inflammatory agents that can help in reducing the complications associated with chronic diseases.
Key Words: Inflammation, Chronic-low level inflammation, Cancer, Diabetes, Phytomedicines
2. Ferrero-Miliani L, Nielsen OH, Andersen PS, et al. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation.Clin. Exp. Immunol. 2007; 147(2): 061127015327006
3. Abbas A.B., Lichtman A.H.Basic Immunology functions and disorders of the immune syste: In Saunders Elsevier, 2009: ISBN :978-1-4160-4688-2.
4. Dandiya PC, Kulkarni SK. Introduction to pharmacology- including toxicology and practicals, Fifth Ed., Vallabh Prakashan, Delhi. 1995; p.131-132
5. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J pharmacol. 2006; 147:232-S240.
6. Calixto JB, Campos MM, Otuki MF et al. Anti-inflammatory compounds from plant origion. Part II. Modulation of pro inflammatory cytokines, chemokines and adhesion molecules. Planta medica.2004; 70:93-103
7. Kale M, Misar AV, Dave V, et al. Anti-inflammatory activity of Dalbergia laceolaria bark ethanol extracts in mice and rats. Ethnopharmacol.2007; 12:300-4.
8. Hussain SP1, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003; 3:276-285.
9. Singh T, Newman. Inflammatory markers in population studies of aging. Ageing Res Rev.2011; 10(3):319–329
10. Tomiyama H, Okazaki R, Koji Yet al. Elevated C-reactive protein: a common marker for atherosclerotic cardiovascular risk and subclinical stages of pulmonary dysfunction and osteopenia in a healthy population. Atherosclerosis. 2005; 178:187-192
11. Kundu, J. K., Surh, Y.-J. Inflammation: gearing the journey to cancer. Mutat Res.2008; 659(1-2):15–30.
12. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev.Cancer.2009; 9(5):361–371
13. Horinaga M, Okita H, Nakashima J, et al. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology. 2005; 66:671-675.
14. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002; 62:6659-6666.
15. Tam L, McGlynn LM, Traynor P. et al. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007; 97:378-383.
16. Klein B, Zhang XG, Jourdan M, et al. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr Top Microbiol Immunol.1990; 166:23-31.
17. Nappo, F., Esposito, K., Cioffi, M., et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002; 39(7):1145–1150
18. Ortega Martinez de Victoria, E., Xu, X., Koska, J., et al. Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes. 2009; 58(2):385–393
19. Bastard, J.-P., Maachi, M., Lagathu, C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006; 17(1):4–12
20. Hong, T., Tan, A. G., Mitchell, P. A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv Ophthalmol. 2011; 56(3):184–194
21. Cao D, Li H, Yi J, et al. Antioxidant properties of the mung bean flavonoids on alleviating heat stress. PloS one. 2011; 6(6):21-71
22. Singh T, Newman. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011; 10(3):319–329
23. Yaffe, K., Lindquist, K., Penninx, B. W., et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003; 61(1):76–80.
24. Gveric D, Kaltschmidt C, Cuzner ML, et al. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol.1998; 57:168-178.
25. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993; 5, 583-588.
26. Rutgeerts P, Geboes K. Understanding inflammatory bowel disease--the clinician's perspective. Eur J Surg Suppl.2001; 66-72.
27. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology.1997; 113:118-126.
28. Kaser, A., Tilg, H. Metabolic aspects in inflammatory bowel diseases. Curr Drug Deliv. 2011; 72:210-218.
29. Jha, R. K., Ma, Q., Sha, H., et al. Acute pancreatitis: a Literature review. Med Sci Monit. 2009; 15(7):RA147–56
30. Ferrucci, L., Semba, R. D., Guralnik, J. M., et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010; 115(18):3810–3816
31. Kadetoff, D., Lampa, J., Westman, M., Andersson, M., et al. Evidence of central inflammation in fibromyalgia - Increased cerebrospinal fluid interleukin-8 levels. J. Neuroimmunol. 2011; 14:1-25.
32. Rolland, Y., Abellan van Kan, G., Gillette-Guyonnet, S., and Vellas, B. Cachexia versus sarcopenia.Current Opinion in Clinical Nutrition and Metabolic. Diabetes Care. 2011; 14(1):15–21
33. Deon D, Ahmed S, Tai K, et al.Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol.2001; 167:5395-5403.
34. Wahida B, Abderrahman B, Nabil C. Antiulcerogenic activity of zizyohus lotus (L) extracts. J Ethanopharmacol. 2007; 112:228-31.
35. Little CV, parsons T, Little C. Personal communication. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2002; (1):CD002947
36. Chrubasik S. Osteoarthritis: Pharmacology and clinical indications of selected botanicals. The pain clinic. 2004; 16:1-16.
37. Bliddal H, Rosetzsky A and Schlichting P. A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage.2000; 8:9-12.
38. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum. 2001; 44:2531-2538.
39. Wigler I, Grotto I, Caspi D, Yaron M. The effects of Zintona EC (a ginger extract) on symptomatic gonarothritis. Osteoarthritis cartilage. 2003; 11:783-789
40. Kimmatkar N, Thawani V, Hingorani L et al. Efficacy and tolerability of Boswellia serata extract in treatment of osteoarthritis of knee –a randomized double blind placebo trail. Phytomedicine. 2003; 10:3-7
41. Belch JJF, Ansell D, Madhok R. Effect of altering dietary essential fatty acids on requirements for non-steroidalanti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Diseases. 1988; 47:96-104.
42. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with black currant seed oil. Rheumatol. 1994;33:847- 852
43. Zurier RB, Rossetti RG, Jacobson EW. Gamma linolenic acid treatment of rheumatoid arthritis. Arth Rheum. 1996; 39:1808-1817.
44. Boursinos LA, Karachalios T, Poultsides L et al. Do steroids, conventional nonsteroidal anti-inflammatory drugs and selective cox-2 inhibitors adversely affect fracture healing? J Musculoskelet Neuronal Interact. 2009; 9(1):44-52.
45. Luna SPL, Basilio AC, Steagall VMP, et al. Evaluation of adverse effects of long term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen and meloxicam in dogs. AJVR. 2007; 68(3):258-264
46. Alexandrina LD. Antibiotics and Antiseptics in Periodontal therapy: Berlin /Heidlburg, Springer verlang.2010.
47. Handa SS, Chawla AS, Sharma AK. Fitoterapia. 1992; 63(1):3-30.
48. Arens CM, Okpanyi SN. Planta Medica.1990; 56:656-657.
49. Srinivasan K, Muruganandan S, Lal J, et al. Evaluation of anti inflammatory activity of pongamia pinnata in rats. J. Ethanopharmacol. 2001; 78:151-157.
50. Hewett JA, Roth RA. Hepatic and extra hepatic pathobiology of bacterial lipopolysaccharides. Pharmacol Rev. 1993; 45:382-411
51. Watson WH, Zhao y, Chawla RK, S. adenosylmethionine attenuates the lipodpolysaccharide induced expression of the gene for tumour necrosis factor alpha. Biochem j. 1999; 342:21-5
52. Kubes P, Mc Cafferty DM. Nitric oxide and intestinal inflammation.Am.J. Med. 2000; 109:150-8
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).